Current
16.4×
5-Year Average
56.8×
All-Time High
440.5×
All-Time Low
13.1×
P/FCF Ratio daily chart for ResMed (RMD)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for ResMed (RMD) from 2002 to 2025
| 2025 | $37.79B | $1.66B | 22.8× | +1.5× | |
| 2024 | $27.46B | $1.29B | 21.3× | -36.1× | |
| 2023 | $32.12B | $559.30M | 57.4× | -99.8× | |
| 2022 | $30.68B | $195.11M | 157.2× | +99.3× | |
| 2021 | $35.89B | $619.89M | 57.9× | +18.0× | |
| 2020 | $27.80B | $696.32M | 39.9× | -6.6× | |
| 2019 | $17.75B | $381.71M | 46.5× | +12.4× | |
| 2018 | $14.79B | $433.57M | 34.1× | +1.8× | |
| 2017 | $11.06B | $342.58M | 32.3× | +13.8× | |
| 2016 | $8.89B | $480.10M | 18.5× | -7.0× | |
| 2015 | $7.94B | $311.24M | 25.5× | +2.6× | |
| 2014 | $7.12B | $310.11M | 22.9× | +3.7× | |
| 2013 | $6.38B | $331.04M | 19.3× | +5.4× | |
| 2012 | $4.45B | $322.05M | 13.8× | -8.9× | |
| 2011 | $4.72B | $208.19M | 22.7× | -13.7× | |
| 2010 | $4.61B | $126.57M | 36.4× | +11.8× | |
| 2009 | $3.07B | $124.66M | 24.6× | -18.9× | |
| 2008 | $2.70B | $62.06M | 43.5× | -192.6× | |
| 2007 | $3.20B | $13.55M | 236.1× | — | |
| 2006 | $3.55B | −$3.72M | — | — | |
| 2005 | $2.30B | $31.39M | 73.4× | -15.9× | |
| 2004 | $1.72B | $19.30M | 89.3× | +50.6× | |
| 2003 | $1.30B | $33.65M | 38.8× | -83.4× | |
| 2002 | $910.92M | $7.46M | 122.2× | — |
- 202522.8×
- 202421.3×
- 202357.4×
- 2022157.2×
- 202157.9×
- 202039.9×
- 201946.5×
- 201834.1×
- 201732.3×
- 201618.5×
- 201525.5×
- 201422.9×
- 201319.3×
- 201213.8×
- 201122.7×
- 201036.4×
- 200924.6×
- 200843.5×
- 2007236.1×
- 2006—
- 200573.4×
- 200489.3×
- 200338.8×
- 2002122.2×
About P/FCF Ratio at ResMed (RMD)
ResMed (RMD) P/FCF ratio is 16.4× as of June 5, 2026. The 5-year average is 56.8×. The sector median currently stands at 19.8×. The current ratio is at the 0th percentile of its own 10-year history.
ResMed (RMD) historical P/FCF ratio has ranged from a low of 13.1× (2011) to a high of 440.5× (2002) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
ResMed P/FCF Ratio by Year
ResMed P/FCF Ratio 2025: 22.8×
ResMed (RMD) P/FCF ratio in 2025 was 22.8×, expanded from 21.3× the prior year.
ResMed P/FCF Ratio 2024: 21.3×
ResMed (RMD) P/FCF ratio in 2024 was 21.3×, contracted from 57.4× the prior year.
ResMed P/FCF Ratio 2023: 57.4×
ResMed (RMD) P/FCF ratio in 2023 was 57.4×, contracted from 157.2× the prior year.
ResMed P/FCF Ratio 2022: 157.2×
ResMed (RMD) P/FCF ratio in 2022 was 157.2×, expanded from 57.9× the prior year.
ResMed P/FCF Ratio 2021: 57.9×
ResMed (RMD) P/FCF ratio in 2021 was 57.9×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of ResMed (RMD), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
ResMed (RMD) Key Financials
Charts, filings, and peer comparison for every metric